Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.38 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 3/20 | 0.36 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BPTF | Q12830 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxalic Acid SCHEMBL10470573 | 0.88 | CHRNB4 (0.41) | CHRNB4CHRNA3CHRNB2CHRNA4HTR2C | |
| SCHEMBL9660310 | 0.78 | TSHR (0.52) | — | |
| SCHEMBL1036653 | 0.76 | CHRNB2 (0.45) | CHRNB4CHRNA3CHRNB2CHRNA4HTR2C | |
| SCHEMBL2588122 | 0.76 | SLC6A2 (0.44) | CHRNB4CHRNA3HTR2CHTR2ACYP2D6 | |
| SCHEMBL29598614 | 0.76 | SLC6A2 (0.44) | CHRNB4CHRNA3HTR2CHTR2ACYP2D6 | |
| SCHEMBL22996317 | 0.75 | CHRNB2 (0.40) | CHRNB4CHRNA3CHRNB2CHRNA4HTR2C | |
| SCHEMBL13116601 | 0.74 | CHRNB4 (0.55) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL13116598 | 0.72 | ADRA2A (0.41) | — | |
| SCHEMBL3446940 | 0.70 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4HTR2C | |
| SCHEMBL13116593 | 0.70 | TSHR (0.32) | CHRNB4CHRNA3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2684874-B1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | CEPHALON INC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051547-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-4910198-A | Antiarrhythmia agent | ORTHO PHARMACEUTICAL CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
| US-4910198-A | Antiarrhythmia agent | ORTHO PHARMACEUTICAL CORPORATION (US) | 1990-03-20 | — | — | US | disclosed |
| US-4855426-A | Process of preparing 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4855426-A | Process of preparing 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4761413-A | CYTOPROTECTION, ANTISECRETORY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
| US-4761413-A | CYTOPROTECTION, ANTISECRETORY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | CHRNB4 4782/4885CHRNA3 3731/4885CHRNB2 4612/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | CHRNB4 4290/4885CHRNA3 4261/4885CHRNB2 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.